Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03836001 · ClinicalTrials.gov registry record · Phase 2
A Neurokinin-1 Receptor Antagonist for the Treatment of Pruritus in Patients With Epidermolysis Bullosa
A Phase 2 study of Epidermolysis Bullosa, sponsored by Stanford University.
- Completed
- Registry status
- Phase 2
- Development phase
- 28
- Enrollment target
- 1
- Study location
NCT03836001 is a Phase 2 study of Epidermolysis Bullosa that has completed, run by Stanford University. The registered enrollment target is 28 participants, above the 17-participant average among 10 other Epidermolysis Bullosa trials with a reported enrollment target (65% higher). The trial reports 1 study location across 1 state.
The verdict
NCT03836001, a Phase 2 study of Epidermolysis Bullosa, has completed, sponsored by Stanford University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 28 participants
- Enrollment target
- 1
- Study location
Study Summary
To determine if Serlopitant (when taken by mouth) is safe and works on itch in patients aged 13 and above with EB.
Conditions Studied
Interventions
- DRUG Placebo Oral Tablet
- DRUG Serlopitant Tablet
Study Locations (1)
California
- Stanford University - Redwood City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 28 participants |
| Start Date | 2019-04-18 |
| Est. Completion | 2022-06-24 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03836001
The ClinicalTrials.gov registry entry for NCT03836001 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 28 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 17-participant average among 10 other Epidermolysis Bullosa trials with a reported enrollment target (65% higher). The listed sponsor is Stanford University, which has 1,744 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Epidermolysis Bullosa appearing as the primary indexed condition, and to 2 interventions - of which Placebo Oral Tablet is the first listed.
NCT03836001 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT03836001 about?
NCT03836001 is a clinical study titled "A Neurokinin-1 Receptor Antagonist for the Treatment of Pruritus in Patients With Epidermolysis Bullosa". To determine if Serlopitant (when taken by mouth) is safe and works on itch in patients aged 13 and above with EB.
What is the current status of trial NCT03836001?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 28 participants. The study started on 2019-04-18. Estimated completion is 2022-06-24.
What conditions does trial NCT03836001 study?
This clinical trial studies the following conditions: Epidermolysis Bullosa.
What interventions are being tested in trial NCT03836001?
The interventions under investigation include: Placebo Oral Tablet (DRUG), Serlopitant Tablet (DRUG).
Who is sponsoring clinical trial NCT03836001?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03836001 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Epidermolysis Bullosa
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study of Effectiveness and Safety of SD-101 in Participants With Epidermolysis Bullosa
COMPLETED · Phase 2
-
Neurokinin-1 Receptor Antagonist for the Treatment of Itch in EB Patients
COMPLETED · Phase 2
-
Study of Alwextin® Cream in Treating Epidermolysis Bullosa
COMPLETED · Phase 2
-
Targeting Collagen VII Antibodies With IV IgG in Dystrophic Epidermolysis Bullosa
RECRUITING · Phase 1
-
A Phase 3b Study for the Treatment of Dystrophic Epidermolysis Bullosa (DEB) in New and Previously EB-101 Treated Patients
ACTIVE NOT RECRUITING · Phase 3
-
Allogeneic ABCB5-positive Dermal Mesenchymal Stromal Cells for Treatment of Epidermolysis Bullosa (Phase III)
ACTIVE NOT RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.